Company Directory / research
PrivateFor profitresearchChuo City, Japan
Cellusion
Cellusion is a developer of corneal endothelial regenerative medicine intended to improve world visibility.
- Founded
- 2015 11 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $4.4B as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
11 years old.
Reach
Website ranked #7,256,597 in the world for traffic, about 838 visits a month.
What it does
BiotechnologyHealth CareMedical
Funding, as listed
$4.4B currency not stated
- Rounds4
- LatestSeries c, Jun 2023
- Investors14, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Cellusion, field by field. Contact details are held but never shown.
The company
- Name
- Cellusion
- Type
- For profit
- Status
- Private
- Founded
- 2015
- Founders
- Satoshi Hato
- Industry
- research
- Categories
- Biotechnology, Health Care, Medical
Where
- City
- Chuo City
- Country
- Japan
- Markets
- Asia-Pacific (APAC)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #7,256,597
- Monthly web visits
- 838
Funding, as listed
- Total
- 4,400,000,000 (currency not stated)
- Rounds
- 4
- Latest round
- Series c
- Latest round date
- Jun 2023
- Investors
- 14
- Lead investors
- 4
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Cellusion may be growing as it is mentioned as a key player in the Corneal Endothelial Keratoplasty market, which is a specific niche within the regenerative medicine industry. The inclusion in a SWOT analysis alongside reputable institutions indicates recognition in its field. Furthermore, the regenerative medicine market in Japan, a relevant market for Cellusion, is projected to grow significantly, suggesting a favorable environment for the company's growth prospects. The growth of the market could imply potential increases in demand for Cellusion's corneal endothelial regenerative medicine.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in Japan.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 32,492 companies in Japan and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.